WO2006087630A3 - OXYPYRAZOLE HMG Co-A REDUCTASE INHIBITORS - Google Patents

OXYPYRAZOLE HMG Co-A REDUCTASE INHIBITORS Download PDF

Info

Publication number
WO2006087630A3
WO2006087630A3 PCT/IB2006/000334 IB2006000334W WO2006087630A3 WO 2006087630 A3 WO2006087630 A3 WO 2006087630A3 IB 2006000334 W IB2006000334 W IB 2006000334W WO 2006087630 A3 WO2006087630 A3 WO 2006087630A3
Authority
WO
WIPO (PCT)
Prior art keywords
hmg
oxypyrazole
reductase inhibitors
reductase
compounds
Prior art date
Application number
PCT/IB2006/000334
Other languages
French (fr)
Other versions
WO2006087630A2 (en
Inventor
Toni-Jo Poel
Scott Douglas Larsen
Jeffrey Allen Pfefferkorn
Jeffrey Thomas Kohrt
Kevin James Filipski
Roderick Joseph Sorenson
Original Assignee
Warner Lambert Co
Toni-Jo Poel
Scott Douglas Larsen
Jeffrey Allen Pfefferkorn
Jeffrey Thomas Kohrt
Kevin James Filipski
Roderick Joseph Sorenson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co, Toni-Jo Poel, Scott Douglas Larsen, Jeffrey Allen Pfefferkorn, Jeffrey Thomas Kohrt, Kevin James Filipski, Roderick Joseph Sorenson filed Critical Warner Lambert Co
Publication of WO2006087630A2 publication Critical patent/WO2006087630A2/en
Publication of WO2006087630A3 publication Critical patent/WO2006087630A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Novel compounds and pharmaceutical compositions useful as hypocholesterolemic and hypolipidemic agents are described. More specifically, potent inhibitors of the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (“HMG CoA reductase”) are described. Method of using such compounds and compositions to treat subjects, including humans, suffering from hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, Alzheimer’s Disease, benign prostatic hypertrophy (BPH), diabetes and osteoporosis are also described.
PCT/IB2006/000334 2005-02-16 2006-02-07 OXYPYRAZOLE HMG Co-A REDUCTASE INHIBITORS WO2006087630A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US65346905P 2005-02-16 2005-02-16
US60/653,469 2005-02-16
US74869805P 2005-12-08 2005-12-08
US60/748,698 2005-12-08

Publications (2)

Publication Number Publication Date
WO2006087630A2 WO2006087630A2 (en) 2006-08-24
WO2006087630A3 true WO2006087630A3 (en) 2006-10-05

Family

ID=36739908

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/000334 WO2006087630A2 (en) 2005-02-16 2006-02-07 OXYPYRAZOLE HMG Co-A REDUCTASE INHIBITORS

Country Status (1)

Country Link
WO (1) WO2006087630A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013510163A (en) 2009-11-06 2013-03-21 チェルシー・セラピューティクス，インコーポレイテッド Enzyme inhibitory compounds
BR112013004882A2 (en) 2010-08-31 2016-05-03 Snu R&Db Foundation use of fetal reprogramming of ppar delta agonist

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986000307A2 (en) * 1984-06-22 1986-01-16 Sandoz Ag Pyrazole analogs of mevalonolactone and derivatives thereof, processes for their production and their use
WO1986007054A1 (en) * 1985-05-22 1986-12-04 Sandoz Ag Imidazole analogs of mevalonolactone and derivatives thereof
EP0252476A2 (en) * 1986-07-07 1988-01-13 Warner-Lambert Company Trans-6-[2-(N-heteroaryl-3,5-disubstituted) pyrazol-4-yl)-ethyl]- or ethenyl] tetrahydro-4-hydroxypyran-2-one-derivatives a process for their preparation and the use thereof
EP0433842A2 (en) * 1989-12-21 1991-06-26 ZAMBON GROUP S.p.A. 1,2,3-Triazole derivatives active as inhibitors of the enzyme HMG-COA reductase and pharmaceutical compositions containing them
WO2004005250A1 (en) * 2002-07-08 2004-01-15 Ranbaxy Laboratories Limited Hmg-coa reductase inhibitors
WO2004105752A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives as hmg-coa reductase inhibitors
WO2006056845A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1986000307A2 (en) * 1984-06-22 1986-01-16 Sandoz Ag Pyrazole analogs of mevalonolactone and derivatives thereof, processes for their production and their use
WO1986007054A1 (en) * 1985-05-22 1986-12-04 Sandoz Ag Imidazole analogs of mevalonolactone and derivatives thereof
EP0252476A2 (en) * 1986-07-07 1988-01-13 Warner-Lambert Company Trans-6-[2-(N-heteroaryl-3,5-disubstituted) pyrazol-4-yl)-ethyl]- or ethenyl] tetrahydro-4-hydroxypyran-2-one-derivatives a process for their preparation and the use thereof
EP0433842A2 (en) * 1989-12-21 1991-06-26 ZAMBON GROUP S.p.A. 1,2,3-Triazole derivatives active as inhibitors of the enzyme HMG-COA reductase and pharmaceutical compositions containing them
WO2004005250A1 (en) * 2002-07-08 2004-01-15 Ranbaxy Laboratories Limited Hmg-coa reductase inhibitors
WO2004105752A1 (en) * 2003-05-30 2004-12-09 Ranbaxy Laboratories Limited Substituted pyrrole derivatives as hmg-coa reductase inhibitors
WO2006056845A1 (en) * 2004-11-23 2006-06-01 Warner-Lambert Company Llc 7-(2h-pyrazol-3-yl)-3, 5-dihyroxy-heptanoic acid derivatives as hmg co-a reductase inhibitors for the treatment of lipidemia

Also Published As

Publication number Publication date
WO2006087630A2 (en) 2006-08-24

Similar Documents

Publication Publication Date Title
TW200626556A (en) Novel pyrazole-based HMG CoA reductase inhibitors
WO2005014539A3 (en) Pyrrole-based hmg-coa reductase inhibitors
BR0116785A (en) Process for synthesizing Form V of atorvastatin and phenylboronates as intermediate compounds
TW200724688A (en) Process for producing atorvastatin, pharmaceutically acceptable salts thereof and intermediates thereof
WO2004001002A3 (en) Novel anticholesterol compositions and method for using same
WO2005105738A3 (en) Salt forms of atorvastatin
NL970034I1 (en) Trans-6-2- (3- or 4-carbonamido-substituted pyrrol-1-yl) alkyl-4-hydroxypyran-2-one as inhibitors of cholesterol synthesis.
DE60239428D1 (en)
WO2007103366A3 (en) Hmg co-a reductase inhibitor enhancement of bone and cartilage
HK1126987A1 (en) Compounds for the treatment of metabolic disorders
IL141786A0 (en) A pharmaceutical composition for treating diabetes containing an ap2 inhibitor
WO2007103873A3 (en) Pharmaceutical formulations of an anhydrous crystal form of 2-(3-fluoro-4-hydroxyphenyl)-7-vinyl-1,3-benzoxazol-5-ol
AU2002251985A1 (en) Display of software notes accessed by content recipient from content provider site
AP2002002641A0 (en) Estrogen agonist metabolites.
EA200601678A1 (en) NEW IMIDAZLES
WO2006087630A3 (en) OXYPYRAZOLE HMG Co-A REDUCTASE INHIBITORS
AU2002310798A1 (en) Pharmaceutical compositions comprising a hmg-coa reductase inhibitor
TW200738624A (en) Novel forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
ATE496025T1 (en) MAGNESIUM SALTS OF HMG-COA REDUCTASE INHIBITORS
BRPI0417138A (en) n-alkyl pyrroles as hmg coa reductase inhibitors
NO20076566L (en) New method for the treatment of hyperlipidemia
DE60234868D1 (en) AMORPH HMG COA REDUCTASE INHIBITORS WITH DESIRED PARTICLE SIZE
DOP2005000228A (en) NEW INHIBITORS OF HMG CO-A REDUCTASA BASED ON PIRAZOL
AU2003214791A1 (en) Process for the preparation of 4-oxytetrahydropyran-2-ones
WO2007057703A3 (en) Intermediate compounds for the preparation of statins

Legal Events

Date Code Title Description
DPE2 Request for preliminary examination filed before expiration of 19th month from priority date (pct application filed from 20040101)
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06710409

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06710409

Country of ref document: EP

Kind code of ref document: A2